Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Operating Leases (2025)

Soleno Therapeutics (SLNO) has disclosed Operating Leases for 1 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases changed N/A to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a N/A change, with the full-year FY2025 number at $2.0 million, changed N/A from a year prior.
  • Operating Leases was $2.0 million for Q4 2025 at Soleno Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.4 million in Q1 2025 to a low of $2.0 million in Q4 2025.